Search Results

Calithera Biosciences, Inc. announced that it intends to hold a special meeting of stockholders on or about June 29, 2023, for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution.

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations.

Xenetic Biosciences, Inc. today announced the appointment of James Parslow, the Company’s Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024.

Calithera Biosciences, Inc., a clinical-stage, precision-oncology biopharmaceutical company, announced its financial results for the third quarter ended September 30, 2022.

Avidity Biosciences, Inc. announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share.

Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).

Pressure BioSciences, Inc. announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering.